Interview: C4XD Chief Sees Indivior Pact As First Of Many

 
• By Kevin Grogan

The deal for an oral orexin-1 receptor antagonist which aims to treat addiction by targeting the craving process validates C4XD's strategy of out-licensing preclinical programs. CEO Clive Dix told Scrip more agreements will follow as the firm "is not a one-trick pony."

Steps
Solid first step: C4XD signs its first major deal • Source: Shutterstock

More from Neurological

More from Therapy Areas